Last kr138.00 SEK
Change Today +0.75 / 0.55%
Volume 80.4K
MVIRB On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
OTC US
Frankfurt
As of 11:30 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

medivir ab-b shs (MVIRB) Snapshot

Open
kr137.00
Previous Close
kr137.25
Day High
kr139.00
Day Low
kr135.00
52 Week High
06/12/14 - kr151.00
52 Week Low
07/31/13 - kr69.25
Market Cap
4.3B
Average Volume 10 Days
105.8K
EPS TTM
kr7.32
Shares Outstanding
30.6M
EX-Date
--
P/E TM
18.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVIR AB-B SHS (MVIRB)

Related News

No related news articles were found.

medivir ab-b shs (MVIRB) Related Businessweek News

No Related Businessweek News Found

medivir ab-b shs (MVIRB) Details

Medivir AB, a research-based specialty pharmaceutical company, develops and markets pharmaceuticals for the treatment of infectious diseases in the Nordic region. It focuses on the research and development of antiviral pharmaceuticals primarily in the hepatitis C area; and other areas, such as bone-related disorders and neuropathic pain. The company also supplies prescription pharmaceuticals, including 16 prescription pharmaceuticals in different therapeutic areas, including Mollipect, Teovent, and Theo-Dur in respiratory organs; Probecid for gout; Nitroglycerin BioPhausia, Digoxin BioPhausia, and Suscard for cardiovascular system; simeprevir for liver disease; Laxabon and Egazil for gastrointestinal system; Xerclear for cold sores; Lithionit and Adasuve for psychiatry; Paraflex for the musculoskeletal system; Citodon and Morfin Special for pain; and Solvezink for zinc deficiency. Medivir AB is headquartered in Stockholm, Sweden.

129 Employees
Last Reported Date: 05/8/14

medivir ab-b shs (MVIRB) Top Compensated Officers

Chief Executive Officer, President and Chief ...
Total Annual Compensation: kr4.8M
Compensation as of Fiscal Year 2013.

medivir ab-b shs (MVIRB) Key Developments

Medivir Announce Availability of Olysio in All Nordic Countries for the Treatment of Adults with Hepatitis C Genotype 1 and 4 Infection

Medivir AB announced that Olysio will be available in all of the Nordic countries within the next few weeks. Treatment with Olysio began in Sweden in late May, followed by Finland and Denmark, where the first patients recently began their treatment. The marketing authorisation granted by the European Commission in mid-May represents a significant milestone in the development of new triple therapy hepatitis C treatment options for genotype 1 and 4 patients. It also includes Olysio as part of an all oral 12-week interferon-free direct-acting antiviral (DAA) regimen with or without ribavirin (RBV), in genotype 1 or 4 patients, who are intolerant to or ineligible for IFN treatment. The European Commission approval for Olysio with PegIFN + RBV is based on a clinical trial programme involving three pivotal phase III studies, QUEST-1, QUEST-2 and PROMISE. The use of Olysio in combination with sofosbuvir was also approved on the basis of, amongst others, the COSMOS clinical phase II study. This study enrolled treatment-naïve patients who were prior null responders. Patients with fibrosis or cirrhosis of the liver were evaluated in all of these studies with very good efficacy and safety data.

Medivir AB Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:00 PM

Medivir AB Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Maris Hartmanis, Chief Executive Officer, President and Chief Executive Officer of Biophausia.

Medivir Announces Approval of Simeprevir in the European Union for the Treatment of Adults with Hepatitis C Genotype 1 and 4 Infection

Medivir AB announced that simeprevir has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C in combination with other medicinal products. This marketing authorisation represents a significant milestone in the development of new triple therapy hepatitis C (HCV) treatment options for genotype 1 and 4 patients. It also includes simeprevir as part of an all oral 12-week interferon-free direct-acting antiviral (DAA) regimen with or without ribavirin (RBV), in genotype 1 or 4 patients, who are intolerant to or ineligible for IFN treatment. The EC approval for simeprevir with PegIFN + RBV is based on a clinical trial programme involving three pivotal phase III studies, with over 1,000 patients. The trials; QUEST-1, QUEST-2 and PROMISE, explored the use of simeprevir in combination with PegIFN/RBV in treatment-naïve patients and patients who have relapsed after prior interferon-base treatment. All three studies met their primary endpoints and demonstrated that simeprevir in combination with PegIFN/RBV, achieves significant cure rates when compared with PegIFN/RBV alone. The EC approval for the combination of simeprevir and sofosbuvir also contains the phase II study, COSMOS. This was based upon prior null responder and treatment-naïve patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVIRB:SS kr138.00 SEK +0.75

MVIRB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVIRB.
View Industry Companies
 

Industry Analysis

MVIRB

Industry Average

Valuation MVIRB Industry Range
Price/Earnings 18.0x
Price/Sales 8.6x
Price/Book 3.6x
Price/Cash Flow 21.8x
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVIR AB-B SHS, please visit www.medivir.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.